President Donald Trump has signed an executive order to expedite research into psychedelic drugs, including psilocybin and ibogaine, showing potential for treating mental health conditions.
The order aims to reduce bureaucratic hurdles and improve data sharing between the FDA and the Department of Veterans Affairs, facilitating quicker studies.
Currently, many psychedelics are classified as having high abuse potential, limiting scientific research. If the FDA confirms medical benefits, these drugs could be rescheduled for greater clinical use.
The initiative responds to a growing push to research psychedelics for anxiety, depression, and trauma, especially among war veterans who have found traditional antidepressants ineffective.
During the signing, President Trump highlighted ibogaine, citing an 80-90% reduction in depression and anxiety symptoms in patients within a month. However, the full extent of benefits and potential risks, such as ibogaine's potential heart damage, are still under investigation due to past research restrictions.